Description

1. Overview

Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analogue. It stimulates the pituitary gland to release growth hormone, which increases circulating IGF-1 levels. In the U.S., approved tesamorelin products are indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss treatment.

2. Potential Benefits

• Reduction of visceral abdominal fat: The primary approved therapeutic benefit.
• Effects on body composition: Clinical studies have evaluated reductions in excess visceral adipose tissue.
• Growth-hormone pathway activation: Stimulates endogenous growth hormone release.
• Metabolic research: Its effects on IGF-1 and body composition have been investigated in clinical studies.

These benefits should not be interpreted as evidence that tesamorelin is suitable for general weight loss, bodybuilding, or anti-aging purposes.

3. How It Works

Tesamorelin binds to growth-hormone-releasing-factor receptors and stimulates the pituitary to produce and release endogenous growth hormone. Growth hormone then influences processes including fat metabolism and increases IGF-1 levels.

4. Tesamorelin 10 mg

10 mg represents the stated amount of tesamorelin in a particular product. It is not the same as an approved daily dose. Current FDA-approved formulations have different strengths and dosing instructions—for example, EGRIFTA SV is supplied as 2 mg/vial with a recommended dose of 1.4 mg once daily, while EGRIFTA WR is supplied as 11.6 mg/vial with a recommended dose of 1.28 mg once daily. These formulations are not interchangeable.

5. Possible Side Effects

Potential adverse effects include:

• Injection-site reactions
• Joint or muscle pain
• Swelling/fluid retention
• Increased IGF-1 levels
• Carpal tunnel syndrome
• Increased blood glucose or diabetes
• Hypersensitivity reactions

6. Important Safety Information

Tesamorelin is contraindicated in pregnancy, active malignancy, certain disorders affecting the hypothalamic-pituitary axis, and known hypersensitivity to tesamorelin or its ingredients. Treatment requires attention to IGF-1 levels and glucose metabolism. Long-term cardiovascular safety has not been established.

7. Conclusion

Tesamorelin 10 mg is a peptide product containing a stated amount of tesamorelin. Tesamorelin has an established prescription indication for reducing excess abdominal fat associated with HIV lipodystrophy, but 10 mg should not be presented as a standard therapeutic dose. The exact formulation and source should be verified before making dosing or administration claims.